Benefits
DashboardNot registered yet? Get a free account.
Sign UpNot registered yet? Get a free account.
Sign Up
You're about to leave our website and go to an external link. Are you sure?
The company is engaged in pharmaceutical industry.
Cadila Pharmaceuticals Limited, is an unlisted public company incorporated on 28 February, 1991. It is classified as a public limited company and is located in Ahmedabad, Gujarat. It's authorized share capital is INR 120.65 cr and the total paid-up capital is INR 80.01 cr.
Read more
Buy Dashboard using Credits
This action will use 1 of your credits. Are you sure you want to go ahead?
Credits Balance:
0
** All rupee values in INR crores. Based on March 2024 numbers.
0.1%
112.06%
521.68%
17.75%
39.4%
23.09%
0.55
4.23
2.36
3.47
5.48
0.11
Buy Report or Plans
Company dashboard
Five year financials and ratios
Risk analysis
Interactive charts
All financials
All annual returns
MoA and AoA
Latest financials
Latest annual return
MoA and AoA
Five year financials and ratios
Shareholding and group structure
Litigation and more
Everything in financial report
Peers and financials
* GST not included
** Reports & MCA filings will be based on the latest available financials.
India
(37)
| State | Type | Address |
|---|
Locations on Map
Filter (4)
Severe Risk
Moderate Risk
Low Risk
Read more
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Sales | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Gross margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Networth | |||||
| Borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Debt to equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ROE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| WC days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Equity Capital | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Reserves | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Borrowings + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Long term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Short term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade payables + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other liabilities + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| CWIP | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Intangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| LT loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Inventories | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade receivables | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cash and cash equivalents | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ST loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Sales + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Sales growth % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Expenses + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cost of goods | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Employee cost | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other costs | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other income | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Depreciation | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Exceptional items | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit before tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit - disc. ops | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Solvency + | |||||
| Total Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Debt/Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Assets/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Liquidity + | |||||
| Current Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Quick Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest Coverage | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Performance | |||||
| Gross Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return + | |||||
| Return on Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROCE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return on Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROIC | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Efficiency + | |||||
| Days Payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Inventory | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Receivable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital | |||||
| Cash Conversion Cycle | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital Days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Axis Trustee Services Limited
No. of Loans: 1
Total Amount : 1,569.3 cr
Bank of Baroda
No. of Loans: 3
Total Amount : 825.0 cr
Canara Bank
No. of Loans: 1
Total Amount : 300.0 cr
Bank of Baroda, CFS Branch
No. of Loans: 1
Total Amount : 300.0 cr
Bank of India
No. of Loans: 2
Total Amount : 200.0 cr
Export-Import Bank of India
No. of Loans: 1
Total Amount : 170.0 cr
Axis Bank Limited
No. of Loans: 1
Total Amount : 153.6 cr
HDFC Bank Limited
No. of Loans: 3
Total Amount : 124.2 cr
Corporation Bank
No. of Loans: 1
Total Amount : 75.0 cr
Union Bank of India
No. of Loans: 1
Total Amount : 75.0 cr
| Designation | Name | DIN/PAN | Tenure |
|---|---|---|---|
| Director | Girdhar Prem Balwani | 00328949 | 8 years |
| Managing Director | Rajiv Indravadan Modi
Shareholder
|
01394558 | 34 years |
| Whole-time Director | Ramesh Ratilal Choksi | 06636737 | 11 years |
| Kmp | Renuka Anjanikumar Upadhyay | <HIDDEN> | 0 years |
| Director | Abhijat Chandrakant Sheth | 07937206 | 6 years |
| Director | Parul Nikunj Shah | 09314433 | 1 years |
| CFO | Kamlesh Navaratnalal Shah | <HIDDEN> | 2 years |
| Director | Rajiv Rajiv Modi | 10276899 | 0 years |
| Director | Manvantkumar Shankerlal Rami | 10404588 | 1 years |
| Name | State / Country | Incorporation Year | Paidup Capital |
|---|---|---|---|
| CPL BIOLOGICALS PRIVATE LIMITED | Gujarat | 2009 | ₹ 45.3 Cr |
| Satellite Overseas (Holdings) Ltd. | Isle Of Man | - | - |
| IRM ENERGY LIMITED | Gujarat | 2015 | ₹ 76.1 Cr |
| Cadila Pharmaceuticals (Ethiopia) Plc. | Ethiopia | - | - |
| SOHL Inc. | United States | - | - |
| Cadila Pharmaceuticals (EA) Ltd. | Kenya | - | - |
| Kadera Yakuhin Ltd. | Japan | - | - |
| Cadila Pharmaceuticals (Europe) Ltd. | United Kingdom | - | - |
| OOO Cadila Pharmaceuticals (Russia) Ltd. | Russian Federation | - | - |
| Modavar Pharmaceutical LLC. | United States | - | - |
| RRM Properties LLC. | United States | - | - |
| Interpharma Industries Ltd. | Nigeria | - | - |
| CPL Biologicals US.LLC | United States | - | - |
| RISM Ltd. | Isle Of Man | - | - |
| Cadila Pharmaceuticals (Uzbekistan) LLC | Uzbekistan | - | - |
| CPL PHARMACEUTICALS PRIVATE LIMITED | Gujarat | 2021 | ₹ 80.3 Cr |
| MARTAND AVIATION GLOBAL HOLDINGS LTD | Ireland | - | - |
| CPL Overseas Trading FZE | United Arab Emirates | - | - |
The incorporation date of CADILA PHARMACEUTICALS LIMITED is 28 February, 1991
The authorized share capital of CADILA PHARMACEUTICALS LIMITED is INR ₹ 120.7 Cr.
The paid-up capital of CADILA PHARMACEUTICALS LIMITED is INR ₹ 80.0 Cr.
The registered address of CADILA PHARMACEUTICALS LIMITED is CADILA CORPORATE CAMPUS SARKHEJ DHOLKA ROAD,BHAT AHMEDABAD Gujarat - 382210
The CIN number of CADILA PHARMACEUTICALS LIMITED is U24231GJ1991PLC015132.
Expand
Delete
Collapse
See
details
